A Clinical Study of 6MW3211 Injection in the Treatment of Relapsed/Refractory Lymphoma

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

NCT03328078 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

A Phase II Study of Single-Agent Lenalidomide in Subjects With Relapsed Or Refractory T-Cell Non-Hodgkin's Lymphoma

NCT00655668 ·Status: TERMINATED ·Phase: PHASE2

A Study of PD-1/CTLA-4 Bispecific AK104 in Relapsed or Refractory Peripheral T-cell Lymphoma

NCT04444141 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

NCT04870944 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

NCT03075553 ·Status: TERMINATED ·Phase: PHASE2

Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00014664 ·Status: UNKNOWN ·Phase: PHASE2

A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL Subjects

NCT04317885 ·Status: COMPLETED ·Phase: PHASE1

Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma

NCT04848064 ·Status: RECRUITING ·Phase: PHASE1

A Study of HMPL-689 in Patients With Lymphomas Failed of Standard of Care or no Standard of Care Existed

NCT03128164 ·Status: COMPLETED ·Phase: PHASE1

A Study of Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

NCT03105336 ·Status: COMPLETED ·Phase: PHASE2

Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL

NCT06093841 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Study of Liposome-entrapped Mitoxantrone Hydrochloride Injection in Relapsed/Refractory Peripheral T-cell Lymphoma and NK/T-cell Lymphoma

NCT03776279 ·Status: UNKNOWN ·Phase: PHASE2

A Phase II Study of Linperlisib (YY-20394) in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma

NCT05274997 ·Status: UNKNOWN ·Phase: PHASE2

Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma

NCT04849351 ·Status: COMPLETED ·Phase: PHASE2

Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma

NCT00531284 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma

NCT03484819 ·Status: COMPLETED ·Phase: PHASE2

Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL

NCT06489808 ·Status: RECRUITING ·Phase: PHASE2

Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors

NCT00831844 ·Status: COMPLETED ·Phase: PHASE2

CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma

NCT00659425 ·Status: COMPLETED ·Phase: PHASE1

A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHL

NCT05806099 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Safety and Efficacy of EX103 in Subjects with Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma

NCT06021678 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease

NCT00003210 ·Status: COMPLETED ·Phase: PHASE2

Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

NCT06845241 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2

A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma

NCT05716087 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)

NCT05784441 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1